COMMENT. Molecular genetic testing is important in diagnosis and therapy of infants with CMS. The administration of esterase inhibitors in patients with COLQ mutations can result in serious complications, and an initial short-term beneficial effect may be misleading. Ephedrine (2 to 3 mg/kg/day) was the most effective therapy in the above study. Most patients with COLQ mutations are disabled from infancy, and muscle weakness is progressive and complicated by ventilatory insufficiency and scoliosis. Clinical diagnosis is supported by repetitive CMAP, and increased muscle weakness following administration of pyridostigmine. COLQ gene mutations are the third most common cause of CMS, and occur as frequently as DOK7 mutation cases.
HISTOCHEMICAL ABNORMALITIES IN VARIOUS FORMS OF CONGENITAL MUSCULAR DYSTROPHY
A large Australasian cohort of patients with congenital muscular dystrophy (CMD) was screened to determine the frequency of various forms, in a study at Children 
